• Tag results for Dr reddy

Dr Reddy's to appeal US District Court's decision on sale of generic Buprenorphine and Suboxone film

The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of its product in the US.

published on : 14th July 2018

Dr Reddy's launches anti-epilepsy drug in US market

The drug has been approved by the US Food and Drug Administration (USFDA).

published on : 19th June 2018

Dr Reddy's Laboratories launches Levetiracetam in Sodium Chloride Injection in the US Market

The Levetiracetam in Sodium Chloride Injection brand and generic had US sales of approximately USD 37 million MAT for the most recent twelve months ending in April 2018 according to IMS Health.

published on : 19th June 2018

Dr Reddy's gets EIR from USFDA for Srikakulam plant

The company, without mentioning the contents of the EIR, said the USFDA has maintained OAI status at its API manufacturing plant in Srikakulam.

published on : 26th February 2018

Dr Reddy's Q3 profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr Reddy's Laboratories Ltd posted a 38.5 percent slump in quarterly net profit as sales declined due to pricing pressure in the United States, its biggest market.

published on : 25th January 2018

Rupee rises by 14 paise against dollar; Sensex up 101 points

Most Asian markets were trading higher as solid economic data from the United States and Germany reinforced investors' optimism.

published on : 4th January 2018

Dr Reddy's Labs shares extend losses, down 3 per cent

Meanwhile, BSE earlier in the day sought clarification from the company on reports that Dr Reddy's shares fell on the buzz of issues raised in EIR for Duvvada plant.

published on : 3rd January 2018

Dr Reddy's gets EIR for Vizag plant, but inspection not closed

Dr Reddy's Laboratories today said it has received an establishment inspection report from the US health regulator for its formulation manufacturing facility at Duvvada in Visakhapatnam.

published on : 21st November 2017

Prescient messages about Indian companies circulate in WhatsApp groups

Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated to a private WhatsApp group saying the Indian drugmaker would not post good numbers.

published on : 16th November 2017

Dr Reddy's Laboratories Q2 consolidated net profit down 1 per cent to Rs 305 crore

The drug major had posted a net profit of Rs 308.9 crore in July-September a year ago, DRL said in a filing to BSE.

published on : 31st October 2017

Dr Reddy's stock ends 3 per cent up; market capitalization rises by Rs 1,019 crore

The company said it has received an establishment inspection report from FDA for a unit at its Srikakulam formulations facility.

published on : 28th September 2017

Dr Reddy's shares slip nearly three percent, mcap drops by Rs 1,082 crore

In terms of equity volume, 1.57 lakh shares of the company were traded on BSE and over 17 lakh shares changed hands on NSE during the day.

published on : 8th September 2017

Dr Reddy's gets favourable verdict in patent litigation in US

US District court has issued a judgement in favour to the drug firm, ruling that proposed generic version of Suboxone sublingual film does not infringe the patent of Indivior.

published on : 1st September 2017

Dr Reddy's faces class action suit in US court

DRL has said a law firm representing a purported investor has filed a class action suit in a USA court against the company and its key executives for alleged violations of American federal securities.

published on : 28th August 2017

US bans Indian drugmaker Divi's factory, shares hit three-year low

The FDA also found violations of manufacturing standards at Dr Reddy's Laboratories Ltd's drug plant, also in Vizag, during an inspection.

published on : 22nd March 2017
1 2 >